P300 topography in Alzheimer's disease
1Department of Psychology, University of Southern California, Los Angeles 90089-1061, USA.
Psychophysiology
|May 1, 1995
Summary
This study found distinct P300 brainwave patterns in Alzheimer's disease (AD) patients compared to healthy controls. Alzheimer's patients showed altered P300 topography, indicating potential diagnostic markers.
Area of Science:
- Neuroscience
- Cognitive Neuroscience
- Neurology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Understanding the neurophysiological underpinnings of AD is crucial for early diagnosis and intervention.
- Scalp P300 event-related potential (ERP) topography has been explored as a potential biomarker for neurological conditions.
Purpose of the Study:
- To determine if P300 scalp topography can differentiate individuals with Alzheimer's disease (AD) from healthy controls.
- To test the hypothesis that AD patients exhibit maximal P300 amplitude frontally and reduced amplitude parietally and on the left hemisphere.
Main Methods:
- An auditory oddball paradigm was employed.
- P300 amplitude was measured across frontal, central, parietal, and occipital sites in both hemispheres and midline.
- 26 AD subjects were compared to 26 age-, sex-, handedness-, and education-matched controls.
Main Results:
- Significant differences in P300 distribution were observed between AD patients and controls.
- Controls showed maximal P300 amplitude over parietal areas.
- AD subjects displayed maximal P300 amplitude frontally, with the most substantial reductions over parietal regions. No hemispheric differences were detected.
Conclusions:
- P300 scalp topography effectively distinguishes Alzheimer's disease patients from healthy individuals.
- The findings support the notion that P300 reflects activity from multiple neural generators, differentially affected in AD.
- Altered P300 topography may serve as a valuable neurophysiological marker for Alzheimer's disease.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...